ANAVEX2-73 Study in Parkinson's Disease Dementia

NCT ID: NCT03774459

Last Updated: 2020-10-22

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 132 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2018-07-09
• Study Completion Date: 2020-09-30

Brief Summary

A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of ANAVEX2-73 for Cognitive Impairment in Patients with Parkinson's Disease with Dementia (PDD)

Detailed Description

This is a Phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-group, three-arm, 14-week study in PD patients with dementia. The study includes a 2 week Screening / Baseline Observation Period and a 14-week Treatment Period (including a 2 week Titration Period), and a 2-week Safety Follow-Up Period

Conditions

Parkinsons Disease With Dementia

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

High dose ANAVEX2-73

High dose ANAVEX2-73

Group Type: EXPERIMENTAL

High dose ANAVEX2-73

Intervention Type: DRUG

Active oral capsule

Mid dose ANAVEX2-73

Mid dose ANAVEX2-73

Group Type: EXPERIMENTAL

Mid dose ANAVEX2-73

Intervention Type: DRUG

Active oral capsule

Placebo oral capsule

Placebo oral capsule

Group Type: PLACEBO_COMPARATOR

Placebo oral capsule

Intervention Type: DRUG

Placebo oral capsule

Interventions

High dose ANAVEX2-73

Active oral capsule

Intervention Type: DRUG

Mid dose ANAVEX2-73

Active oral capsule

Intervention Type: DRUG

Placebo oral capsule

Placebo oral capsule

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Diagnosis of idiopathic Parkinson's disease (PD) consistent with the UK Parkinson's Disease Society Brain Bank diagnostic criteria.
• Diagnosis of probable PD dementia (PDD) according to the Movement Disorder Society Task Force clinical diagnostic criteria.
• Montreal Cognitive Assessment (MoCA) score of 13 to 23, inclusive, at Screening.
• Male or female and aged ≥ 50 years.
• Caregivers and subjects (or legal representative) must understand and have signed approved informed consent.
• Caregivers and subjects (or legal representative) must be able to understand study requirements and be willing to follow instructions.
• Stable regimen of anti-Parkinson's disease medications (including levodopa, dopamine agonists, MAO-B inhibitors, or the COMT inhibitor entacapone), which has been stable for at least 4 weeks prior to Baseline.
• Treatment with cholinesterase inhibitor (rivastigmine, donepezil and galantamine (Exelon®, Aricept®, or Reminyl®) will be permitted, provided the dose has been stable for a minimum of 8 weeks prior to randomization.
• Subjects with history of depression on antidepressant medications will be allowed if depression is controlled and they have been on a stable daily dose of the antidepressant for ≥8 weeks before Baseline.
• Contraception:

• Women of childbearing potential must use an acceptable method of contraception starting 4 weeks prior to study drug administration and for a minimum of 4 weeks after study completion. Otherwise, women must be postmenopausal (at least one year absence of vaginal bleeding or spotting) as confirmed by FSH greater than or equal to 40 mIU/mL or 40 IU/L or be surgically sterile.
• Men with a potentially fertile partner must have had a vasectomy or be willing to use an acceptable method of contraception for the duration of the study and for 3 months after study drug discontinuation.

Exclusion Criteria

• History of any significant neurologic or psychiatric disorder other than PD that can contribute to cognitive impairment.
• Any other condition or clinically significant abnormal findings like severe co-morbidities e.g. history of stroke, poor kidney or liver function on the physical or neurological examination, medical and psychiatric history, at screening or at baseline that, in the opinion of the Investigator, would make the subject unsuitable for the study.
• Potential symptomatic causes of cognitive impairment including but not limited to

1. abnormal thyroid function test at screening (TSH)

2. abnormal B12 level at screening

3. MRI findings (by history) pointing to a potential symptomatic cause of cognitive dysfunction, including significant vascular changes, or communicating hydrocephalus.

• Treatment with memantine or amantadine. If appropriate the drugs can be discontinued for a minimum of 4 weeks prior to randomization.
• Use of over the counter (OTC) or prescription medication for sleep on 2 or more occasions per week (less than that is allowed).
• History of depression as measured by Beck Depression Inventory score >17 at screening.
• Treatment with any other investigational drug or device within 4 weeks prior to screening.
• Smoking > 1 pack of cigarettes per day (as assessed for the 4 weeks prior to screening).
• Women who are pregnant or lactating.
• Known allergy or sensitivity to ANAVEX2-73 or any of its components.
• Suicidal ideation on the Columbia Suicide Severity Rating Scale (C-SSRS) of type 4 or type 5, or any suicidal behavior, in the past 6 months. Type 4 indicates active suicidal ideation with some intent to act, without a specific plan. Type 5 indicates active suicidal ideation with a specific plan and intent.
• Use of centrally acting anticholinergic drugs during the 4 weeks before randomization.
• Medications used for overactive bladder will be allowed provided that the regimen has been stable 4 weeks prior to randomization.
• Treatment with any dopamine receptor blocking medications with the exception of low dose quetiapine (≤50 mg/day). Pimavanserin (≤34 mg/day) will be allowed.
• History of neurosurgical intervention (e.g., deep brain stimulation) for PD.
• Unpredictable motor fluctuations that would interfere with administering cognitive assessments in the ON state.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 85 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Anavex Germany GmbH

INDUSTRY

Sponsor Role: collaborator

Anavex Life Sciences Corp.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

KaRa MINDS

Macquarie Park, , Australia

Hammond Health

Malvern, , Australia

Hospital Cruces Bilbao

Barakaldo, , Spain

Hospital de la Santa Creu i Sant Pau

Barcelona, , Spain

Hospital Mutua Terrasa

Barcelona, , Spain

Hospital Universitario Vall d'Hebron

Barcelona, , Spain

Hospital Universitario de Burgos

Burgos, , Spain

Hospital Universitario Puerta del Mar

Cadiz, , Spain

Hospital del Henares

Coslada, , Spain

Hospital General Universitario de Elche

Elche, , Spain

Hospital Arquitecto Marcide

Ferrol, , Spain

Hospital Santa Caterina

Girona, , Spain

Clinica Ruber Internacional

Madrid, , Spain

Clínica Universidad de Navarra (CUN) - Sede Madrid- Servicio de Neurología -

Madrid, , Spain

Hospital Clínico San Carlos

Madrid, , Spain

Hospital de La Princesa

Madrid, , Spain

Hospital General Universitario Gregorio Marañón

Madrid, , Spain

Hospital Infanta Leónor

Madrid, , Spain

Hospital Universitario Puerta de Hierro

Madrid, , Spain

Hospital Universitario Ramón y Cajal

Madrid, , Spain

Hospital HM Puerta del Sur

Móstoles, , Spain

Hospital Universitario Central de Asturias (HUCA)

Oviedo, , Spain

Clínica Universidad de Navarra (CUN)

Pamplona, , Spain

Hospital de Santiago de Compostela

Santiago de Compostela, , Spain

Hospital Universitario Virgen del Rocío

Seville, , Spain

Countries

Australia; Spain

Other Identifiers

ANAVEX2-73-PDD-001

Identifier Type: -

Identifier Source: org_study_id